T1	Participants 35 86	after allogeneic hematopoietic cell transplantation
T2	Participants 226 271	allogeneic hematopoietic cell transplantation
T3	Participants 668 713	matched sibling or unrelated donor transplant
T4	Participants 741 805	prolonged sirolimus administration (â‰¥ 1 year post-transplant).
T5	Participants 806 984	Median follow-up time for surviving patients at time of this analysis was 41 months (range 27-60) for sirolimus/tacrolimus and 49 months (range 29-63) for methotrexate/tacrolimus
